Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
12.40
+0.09 (0.73%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.

The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.

The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye.

The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.

The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.

Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics, Inc.
Stoke Therapeutics logo
Country United States
Founded 2014
IPO Date Jun 19, 2019
Industry Biotechnology
Sector Healthcare
Employees 110
CEO Edward Kaye

Contact Details

Address:
45 Wiggins Avenue
Bedford, Massachusetts 01730
United States
Phone 781 430 8200
Website stoketherapeutics.com

Stock Details

Ticker Symbol STOK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001623526
CUSIP Number 86150R107
ISIN Number US86150R1077
Employer ID 47-1144582
SIC Code 2834

Key Executives

Name Position
Dr. Edward M. Kaye M.D., Ph.D. Chief Executive Officer and Director
Dr. Adrian R. Krainer Ph.D. Co-Founder and Independent Director
Dr. Barry S. Ticho FACC, M.D., Ph.D. Chief Medical Officer
Isabel Aznarez Ph.D. Co-Founder and Senior Vice President of Discovery Research
Thomas Edward Leggett Chief Financial Officer
Eric Rojas Head of Investor Relations
Jonathan Allan J.D. Corporate Secretary and General Counsel
Dawn Kalmar Chief Communications Officer
Joan Wood Chief Human Resources Officer
Shamim Ruff M.S. Chief Regulatory Officer

Latest SEC Filings

Date Type Title
Oct 9, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Sep 23, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 19, 2024 144 Filing
Sep 10, 2024 8-K Current Report
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report
Aug 1, 2024 144 Filing
Jul 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jul 2, 2024 144 Filing
Jun 21, 2024 8-K Current Report